The University of British Columbia
UBC - A Place of Mind
The University of British Columbia
Faculty of MedicineThis Changed My Practice (TCMP) by UBC CPD
  • ⌂ Articles
  • Authors
  • Submit an Article
  • Subscribe
  • Key Features | 0.25 cr/article
  • About
  • UBC CPD ↗

» This Changed My Practice » Heart failure

Heart failure

Identifying and treating iron deficiency in patients hospitalized for heart failure

Identifying and treating iron deficiency in patients hospitalized for heart failure

By Hans Haag and Dr. Ricky Turgeon on July 5, 2023

Heart failure is the third leading cause of hospitalization in Canada and leads to readmission in 1 in 5 patients within 30 days after discharge. Iron deficiency (with or without anemia) is an important comorbidity in patients with HF and is associated with worse outcomes. Assess iron deficiency for all patients with HFrEF and HFmrEF admitted for acute HF.

Identifying Advanced Heart Failure in your patient

Identifying Advanced Heart Failure in your patient

By Dr. Michael Diamant on April 19, 2022

The prevalence of ambulatory patients with advanced or end-stage heart failure (HF) is increasing over time, and now comprises as much as 14% of all patients with HF. Patients may be eligible for advanced therapies, including durable mechanical circulatory support (MCS) and heart transplantation, that can change their trajectory and markedly improve long-term survival.

Practice tips for heart failure with reduced ejection fraction (HFrEF): supporting patients with medications and self-monitoring

Practice tips for heart failure with reduced ejection fraction (HFrEF): supporting patients with medications and self-monitoring

By Shari Hurst on April 6, 2022

There are a few tips and tricks to improve medication tolerance and adherence, and improve quality of life for patients with HF-rEF. Multiple studies have shown that a focus on patient education and empowerment along with clinical follow-up for HFrEF medical treatment improves survival, reduces hospitalizations, and improves quality of life.

Heart

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: New drug class in the treatment of Heart Failure with Reduced Ejection Fraction — DAPA-HF and EMPEROR-Reduced trials

By Tanveer Brar BSc BSc(Pharm) ACPR, Doson Chua BSc(Pharm) PharmD FCSHP BCPS BCCP, and Laura Atiyeh on January 13, 2021

Heart failure (HF) is a clinical syndrome associated with significant morbidity and mortality. In 2020, the prevalence of HF was approximately 64.34 million cases (8.52 per 1,000 inhabitants) worldwide and this number has been steadily increasing over time. There is compelling evidence to suggest that in individuals with HFrEF in the presence or absence of T2DM, both dapagliflozin and empagliflozin have profound effects on reduction of HF hospitalizations and possibly CV mortality.

New insight into “HFpEF” – cardiac amyloid no longer a zebra diagnosis?

New insight into “HFpEF” – cardiac amyloid no longer a zebra diagnosis?

By Dr. Alice S Chang, Dr. Michael J Diamant, Dr. Margot K Davis, and Dr. Krishnan Ramanathan on October 30, 2019

Cardiac amyloidosis (CA) is an infiltrative disease that is being increasingly identified in those with HFpEF. Amyloidosis is a group of heterogeneous disorders characterized by the deposition of misfolded protein that aggregates into fibrils, affecting multiple organs including the heart, neural tissues, kidneys, and the gastrointestinal tract.

Cardiology

Diuretic strategies in patients with acute decompensated heart failure

By Dr. Mustafa Toma and Dr. Christopher Cheung on October 15, 2014

In patients presenting with acute decompensated heart failure and previously on oral loop diuretics at home, there is no difference between low-dose and high-dose furosemide, or bolus and continuous infusions, on the patient’s global assessment of symptoms and changes in serum creatinine at 72 hours.

Aldosterone antagonists for the treatment of systolic heart failure

Aldosterone antagonists for the treatment of systolic heart failure

By Drs. Mustafa Toma and Neda Amiri on April 15, 2013

Spironolactone or eplerenone should be added to BB and ACEi/ARB in NYHA class II HF patients with EF < 30-35% in the absence of significant renal impairment or hyperkalemia.


Recent Articles

  • Diagnosis of anxiety conditions in primary care: Part 1
  • Environmental impacts of clinical practice: reducing unnecessary care
  • Buprenorphine/naloxone for chronic non-cancer pain
  • Menopause: Don’t sweat it: Part 1
  • Trauma-informed high impact chronic pain care
  • Letter from the editor

Recent Comments

  • K on Interpretation of Syphilis Serology
  • Scott Brill on Interpretation of Syphilis Serology
  • Dr. Douglas Green on Diagnosis of anxiety conditions in primary care: Part 1
  • Paul Harris on Diagnosis of anxiety conditions in primary care: Part 1
  • Marjolaine Savoie on Identifying and treating iron deficiency in patients hospitalized for heart failure
  • Maryanne C Roy on Diagnosis of anxiety conditions in primary care: Part 1

Visit UBC CPD at ubccpd.ca

UBC CPD website

View all CPD learning activities: virtual, in-person and hybrid conferences, workshops, webinars, online modules, customized community courses, simulation hands-on courses, coaching, mentoring, personalized learning, recordings, and more.

Visit UBC CPD ↗

  • Medical Area
  • Popular Topics
  • Addiction Medicine
  • Allergy/ Immunology
  • Announcements
  • Cardiology
  • Dermatology
  • Emergency Medicine
  • Endocrinology
  • Family Medicine
  • Gastroenterology
  • Geriatrics
  • Hematology
  • Hepatology
  • Infectious Disease
  • Internal Medicine
  • Nephrology
  • Neurology
  • Obstetrics and Gynaecology
  • Oncology
  • Ophthalmology
  • Orthopaedics
  • Otorhinolaryngology or ENT (ear, nose and throat)
  • Palliative Care
  • Pediatrics
  • Physiatry
  • Physical Medicine and Rehabilitation
  • Practice
  • Psychiatry
  • Public Health
  • Respirology
  • Rheumatology
  • Sport Medicine
  • Surgery
  • Teaching
  • Technology
  • Travel Medicine
  • Uncategorized
  • Urology
  • Wellness
  • Addiction Antibiotics Apps Arthritis Atrial fibrillation Beta blockers Billing Blood work Cardiovascular Children Chronic pain Cognitive behavioural therapy Contraception COVID-19 Depression Diabetes Elderly Estrogen Exercise GI tract Guidelines Heart Heart failure Hepatitis C Infants Infections iOS IUD Kidney disease Liver Mental health Opioids Pain Patient handouts Practice change Practice tip Pregnancy Resources Resources for practitioners Sexual medicine Teaching Thrombosis Vaccine Well-being Women's health
    This field is for validation purposes and should be left unchanged.

    Disclaimer
    This Changed My Practice (TCMP) by UBC CPD | Continuing Professional Development
    Faculty of Medicine
    City Square, 200-555 W 12th Ave
    Vancouver, BC Canada V5Z 3X7
    Tel 604 675 3777
    Fax 604 675 3778
    Website ubccpd.ca
    Email tcmp.cpd@ubc.ca
    Find us on
        
    Back to top
    The University of British Columbia
    • Emergency Procedures |
    • Terms of Use |
    • Copyright |
    • Accessibility